NASDAQ:GOSS

Gossamer Bio Competitors

$8.49
-0.36 (-4.07 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.42
Now: $8.49
$8.95
50-Day Range
$8.42
MA: $9.42
$10.64
52-Week Range
$7.92
Now: $8.49
$16.79
Volume448,842 shs
Average Volume671,687 shs
Market Capitalization$641.23 million
P/E RatioN/A
Dividend YieldN/A
Beta1.34

Competitors

Gossamer Bio (NASDAQ:GOSS) Vs. GBT, ITCI, LGND, XNCR, ALXO, and CYRX

Should you be buying GOSS stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Gossamer Bio, including Global Blood Therapeutics (GBT), Intra-Cellular Therapies (ITCI), Ligand Pharmaceuticals (LGND), Xencor (XNCR), ALX Oncology (ALXO), and Cryoport (CYRX).

Gossamer Bio (NASDAQ:GOSS) and Global Blood Therapeutics (NASDAQ:GBT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Institutional and Insider Ownership

72.0% of Gossamer Bio shares are held by institutional investors. 23.3% of Gossamer Bio shares are held by company insiders. Comparatively, 4.3% of Global Blood Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Gossamer Bio has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Comparatively, Global Blood Therapeutics has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Gossamer Bio and Global Blood Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gossamer Bio00503.00
Global Blood Therapeutics051402.74

Gossamer Bio presently has a consensus target price of $23.00, indicating a potential upside of 170.91%. Global Blood Therapeutics has a consensus target price of $90.3158, indicating a potential upside of 121.31%. Given Gossamer Bio's stronger consensus rating and higher probable upside, equities research analysts plainly believe Gossamer Bio is more favorable than Global Blood Therapeutics.

Profitability

This table compares Gossamer Bio and Global Blood Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gossamer BioN/A-64.34%-46.52%
Global Blood Therapeutics-332.94%-56.43%-39.32%

Earnings & Valuation

This table compares Gossamer Bio and Global Blood Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gossamer BioN/AN/A$-180,310,000.00($3.29)-2.58
Global Blood Therapeutics$2.11 million1,202.19$-266,770,000.00($4.71)-8.66

Gossamer Bio has higher earnings, but lower revenue than Global Blood Therapeutics. Global Blood Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Summary

Gossamer Bio beats Global Blood Therapeutics on 8 of the 13 factors compared between the two stocks.

Gossamer Bio (NASDAQ:GOSS) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Earnings & Valuation

This table compares Gossamer Bio and Intra-Cellular Therapies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gossamer BioN/AN/A$-180,310,000.00($3.29)-2.58
Intra-Cellular Therapies$60,000.0042,103.81$-147,720,000.00($2.68)-11.65

Intra-Cellular Therapies has higher revenue and earnings than Gossamer Bio. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Gossamer Bio has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500.

Institutional and Insider Ownership

72.0% of Gossamer Bio shares are held by institutional investors. Comparatively, 79.1% of Intra-Cellular Therapies shares are held by institutional investors. 23.3% of Gossamer Bio shares are held by company insiders. Comparatively, 18.2% of Intra-Cellular Therapies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations for Gossamer Bio and Intra-Cellular Therapies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gossamer Bio00503.00
Intra-Cellular Therapies00703.00

Gossamer Bio presently has a consensus target price of $23.00, indicating a potential upside of 170.91%. Intra-Cellular Therapies has a consensus target price of $47.4286, indicating a potential upside of 51.92%. Given Gossamer Bio's higher probable upside, equities research analysts plainly believe Gossamer Bio is more favorable than Intra-Cellular Therapies.

Profitability

This table compares Gossamer Bio and Intra-Cellular Therapies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gossamer BioN/A-64.34%-46.52%
Intra-Cellular Therapies-1,985.32%-48.27%-42.56%

Summary

Intra-Cellular Therapies beats Gossamer Bio on 8 of the 12 factors compared between the two stocks.

Ligand Pharmaceuticals (NASDAQ:LGND) and Gossamer Bio (NASDAQ:GOSS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Valuation and Earnings

This table compares Ligand Pharmaceuticals and Gossamer Bio's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ligand Pharmaceuticals$120.28 million20.75$629.30 million$2.1171.20
Gossamer BioN/AN/A$-180,310,000.00($3.29)-2.58

Ligand Pharmaceuticals has higher revenue and earnings than Gossamer Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Ligand Pharmaceuticals has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500.

Institutional and Insider Ownership

72.0% of Gossamer Bio shares are held by institutional investors. 10.6% of Ligand Pharmaceuticals shares are held by insiders. Comparatively, 23.3% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Ligand Pharmaceuticals and Gossamer Bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ligand Pharmaceuticals01602.86
Gossamer Bio00503.00

Ligand Pharmaceuticals presently has a consensus price target of $215.60, indicating a potential upside of 43.51%. Gossamer Bio has a consensus price target of $23.00, indicating a potential upside of 170.91%. Given Gossamer Bio's stronger consensus rating and higher probable upside, analysts plainly believe Gossamer Bio is more favorable than Ligand Pharmaceuticals.

Profitability

This table compares Ligand Pharmaceuticals and Gossamer Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ligand Pharmaceuticals-11.23%5.90%3.22%
Gossamer BioN/A-64.34%-46.52%

Summary

Ligand Pharmaceuticals beats Gossamer Bio on 7 of the 13 factors compared between the two stocks.

Xencor (NASDAQ:XNCR) and Gossamer Bio (NASDAQ:GOSS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Valuation and Earnings

This table compares Xencor and Gossamer Bio's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xencor$156.70 million15.63$26.88 million$0.4691.87
Gossamer BioN/AN/A$-180,310,000.00($3.29)-2.58

Xencor has higher revenue and earnings than Gossamer Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Xencor has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500.

Institutional and Insider Ownership

72.0% of Gossamer Bio shares are held by institutional investors. 3.7% of Xencor shares are held by insiders. Comparatively, 23.3% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Xencor and Gossamer Bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Xencor20702.56
Gossamer Bio00503.00

Xencor presently has a consensus price target of $47.1111, indicating a potential upside of 11.48%. Gossamer Bio has a consensus price target of $23.00, indicating a potential upside of 170.91%. Given Gossamer Bio's stronger consensus rating and higher probable upside, analysts plainly believe Gossamer Bio is more favorable than Xencor.

Profitability

This table compares Xencor and Gossamer Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Xencor-113.40%-13.56%-12.03%
Gossamer BioN/A-64.34%-46.52%

Summary

Gossamer Bio beats Xencor on 7 of the 13 factors compared between the two stocks.

ALX Oncology (NASDAQ:ALXO) and Gossamer Bio (NASDAQ:GOSS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Valuation and Earnings

This table compares ALX Oncology and Gossamer Bio's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ALX OncologyN/AN/AN/AN/AN/A
Gossamer BioN/AN/A$-180,310,000.00($3.29)-2.58

Institutional and Insider Ownership

73.5% of ALX Oncology shares are held by institutional investors. Comparatively, 72.0% of Gossamer Bio shares are held by institutional investors. 23.3% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for ALX Oncology and Gossamer Bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ALX Oncology00703.00
Gossamer Bio00503.00

ALX Oncology presently has a consensus price target of $90.6667, indicating a potential upside of 49.29%. Gossamer Bio has a consensus price target of $23.00, indicating a potential upside of 170.91%. Given Gossamer Bio's higher probable upside, analysts plainly believe Gossamer Bio is more favorable than ALX Oncology.

Profitability

This table compares ALX Oncology and Gossamer Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ALX OncologyN/AN/AN/A
Gossamer BioN/A-64.34%-46.52%

Summary

ALX Oncology beats Gossamer Bio on 4 of the 6 factors compared between the two stocks.

Cryoport (NASDAQ:CYRX) and Gossamer Bio (NASDAQ:GOSS) are both transportation companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Volatility and Risk

Cryoport has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500.

Valuation and Earnings

This table compares Cryoport and Gossamer Bio's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cryoport$33.94 million69.29$-18,330,000.00($0.55)-93.76
Gossamer BioN/AN/A$-180,310,000.00($3.29)-2.58

Cryoport has higher revenue and earnings than Gossamer Bio. Cryoport is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cryoport and Gossamer Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cryoport-55.87%-17.68%-11.32%
Gossamer BioN/A-64.34%-46.52%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Cryoport and Gossamer Bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cryoport00703.00
Gossamer Bio00503.00

Cryoport presently has a consensus price target of $72.00, indicating a potential upside of 39.62%. Gossamer Bio has a consensus price target of $23.00, indicating a potential upside of 170.91%. Given Gossamer Bio's higher probable upside, analysts plainly believe Gossamer Bio is more favorable than Cryoport.

Institutional and Insider Ownership

88.3% of Cryoport shares are held by institutional investors. Comparatively, 72.0% of Gossamer Bio shares are held by institutional investors. 11.5% of Cryoport shares are held by insiders. Comparatively, 23.3% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Cryoport beats Gossamer Bio on 7 of the 12 factors compared between the two stocks.


Gossamer Bio Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.81-1.3%$2.54 billion$2.11 million-8.83Analyst Report
Analyst Revision
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.22-3.6%$2.53 billion$60,000.00-9.70
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$150.23-0.9%$2.50 billion$120.28 million-151.75Analyst Report
Decrease in Short Interest
Xencor logo
XNCR
Xencor
1.2$42.26-5.7%$2.45 billion$156.70 million-30.19
ALX Oncology logo
ALXO
ALX Oncology
1.9$60.73-0.6%$2.44 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Cryoport logo
CYRX
Cryoport
1.9$51.57-2.6%$2.35 billion$33.94 million-88.91Gap Down
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.13-5.6%$2.35 billion$15 million-17.35Unusual Options Activity
News Coverage
Gap Down
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$45.22-0.4%$2.25 billion$963.01 million14.04
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$28.96-1.5%$2.21 billion$23.90 million-17.99Analyst Report
Unusual Options Activity
News Coverage
Gap Down
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$50.68-0.8%$2.08 billionN/A0.00Insider Selling
Analyst Revision
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$26.15-0.3%$2.01 billion$103.54 million-19.66Insider Selling
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$124.77-1.5%$2.00 billionN/A-11.27
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$53.44-1.6%$2.00 billionN/A-19.87
Amarin logo
AMRN
Amarin
1.6$5.02-0.2%$1.98 billion$429.76 million-100.38Analyst Revision
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.22-3.5%$1.94 billion$410,000.00-5.92Analyst Report
Gap Down
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$59.69-4.6%$1.91 billionN/A-25.40Increase in Short Interest
Gap Down
MacroGenics logo
MGNX
MacroGenics
1.2$31.83-2.4%$1.91 billion$64.19 million-10.17Decrease in Short Interest
News Coverage
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.73-3.2%$1.90 billion$34.51 million-17.72
Kura Oncology logo
KURA
Kura Oncology
1.6$28.59-3.1%$1.89 billionN/A-17.54
FibroGen logo
FGEN
FibroGen
1.8$19.91-3.1%$1.82 billion$256.58 million-7.63Analyst Report
High Trading Volume
News Coverage
MORF
Morphic
1.3$55.08-0.6%$1.79 billion$16.98 million-35.31Insider Selling
Decrease in Short Interest
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$38.00-0.0%$1.77 billion$14.87 million-14.18Increase in Short Interest
News Coverage
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.70-0.7%$1.77 billion$26.87 million-12.93Insider Selling
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.8$5.89-0.2%$1.77 billion$1.63 billion14.37Analyst Report
Decrease in Short Interest
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.61-2.2%$1.71 billion$428.41 million15.38News Coverage
Gap Down
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.7$31.70-0.5%$1.68 billion$392.76 million13.15Analyst Upgrade
Analyst Revision
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.06-1.0%$1.64 billionN/A-6.43Increase in Short Interest
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$17.87-0.8%$1.63 billion$145.97 million-7.23
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.29-1.4%$1.60 billion$2.34 million-9.87
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.15-0.5%$1.60 billionN/A0.00Analyst Revision
News Coverage
Generation Bio logo
GBIO
Generation Bio
1.8$28.30-2.8%$1.60 billionN/A0.00Insider Selling
Increase in Short Interest
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.35-2.0%$1.57 billion$320,000.00-8.40News Coverage
uniQure logo
QURE
uniQure
1.7$34.07-4.1%$1.53 billion$7.28 million-9.04Insider Selling
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$24.95-4.0%$1.51 billion$175.34 million-14.68Analyst Downgrade
Analyst Revision
News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.52-2.4%$1.50 billion$82.27 million-18.34Gap Down
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$32.24-5.2%$1.50 billionN/A0.00Analyst Upgrade
News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$41.84-3.6%$1.47 billionN/A0.00
OLMA
Olema Pharmaceuticals
1.6$36.14-2.1%$1.45 billionN/A0.00Increase in Short Interest
News Coverage
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$32.37-0.9%$1.45 billionN/A0.00Insider Selling
Increase in Short Interest
Endo International logo
ENDP
Endo International
1.3$6.26-3.4%$1.44 billion$2.91 billion-9.21
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$28.51-0.7%$1.42 billion$19.89 million-13.45Analyst Report
News Coverage
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$21.71-1.0%$1.42 billion$73.41 million-4.59
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.56-0.8%$1.41 billion$6.20 million-14.28News Coverage
Zymeworks logo
ZYME
Zymeworks
1.8$30.38-0.7%$1.40 billion$29.54 million-8.06Unusual Options Activity
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$34.85-0.7%$1.39 billionN/A-145.21
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$26.68-1.3%$1.38 billion$4.23 million-19.76Increase in Short Interest
Gap Down
ATBPD
Antibe Therapeutics
0.1$3.57-0.3%$1.38 billion$7.51 million-5.95Gap Down
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$27.52-4.2%$1.38 billionN/A-2.98Gap Down
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$56.67-12.0%$1.32 billionN/A0.00Increase in Short Interest
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.